CRISPR/Cas9 DNA cleavage at SNP-derived PAM enables both in vitro and in vivo KRT12 mutation-specific targeting

Gene Therapy

Volumn 23, Issue 1, 2016, Pages 108-112

  Courtney, D G ^a   Moore, J E ^a,b   Atkinson, S D ^a   Maurizi, E ^a   Allen, E H A ^c   Pedrioli, D M L ^c   Mclean, W H I ^c   Nesbit, M A ^a   Moore, C B T ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b Cathedral Eye Clinic Belfast   (Ireland)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY RNA; GENOMIC DNA; MESSENGER RNA; CYTOKERATIN 12; KRT12 PROTEIN, MOUSE;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CORNEA STROMA; DNA CLEAVAGE; DNA END JOINING REPAIR; EXPERIMENTAL MODEL; FEMALE; GENE; IN VITRO STUDY; IN VIVO STUDY; MEESMANN CORNEAL DYSTROPHY; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; C57BL MOUSE; CRISPR CAS SYSTEM; GENE TARGETING; GENE THERAPY; GENETICS; HETEROZYGOTE; METABOLISM; MISSENSE MUTATION; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE;

ALLELES; ANIMALS; BASE SEQUENCE; CRISPR-CAS SYSTEMS; DNA CLEAVAGE; FEMALE; GENE TARGETING; GENETIC THERAPY; HETEROZYGOTE; KERATIN-12; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84955199174     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2015.82     Document Type: Article

References (22)

1. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014; 157: 1262-1278
2. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS et al. Genomescale CRISPR-Cas9 knockout screening in human cells. Science 2014; 343: 84-87
3. Wang T, Wei JJ, Sabatini DM, Lander ES. Genetic screens in human cells using the CRISPR-Cas9 system. Science 2014; 343: 80-84
4. Westra ER, Semenova E, Datsenko KA, Jackson RN, Wiedenheft B, Severinov K et al. Type I-E CRISPR-cas systems discriminate target from non-target DNA through base pairing-independent PAM recognition. PLoS Genet 2013; 9: e1003742
5. Smith C, Abalde-Atristain L, He C, Brodsky BR, Braunstein EM, Chaudhari P et al. Efficient and allele-specific genome editing of disease loci in human iPSCs. Mol Ther 2014; 23: 570-577
6. Yoshimi K, Kaneko T, Voigt B, Mashimo T. Allele-specific genome editing and correction of disease-associated phenotypes in rats using the CRISPR-Cas platform. Nat Commun 2014; 5: 4240
7. Liao H, Irvine AD, Macewen CJ, Weed KH, Porter L, Corden LD et al. Development of allele-specific therapeutic siRNA in Meesmann epithelial corneal dystrophy. PLoS One 2011; 6: e28582
8. Kao WW, Liu CY, Converse RL, Shiraishi A, Kao CW, Ishizaki M et al. Keratin 12-deficient mice have fragile corneal epithelia. Invest Ophthalmol Vis Sci 1996; 37: 2572-2584
9. Courtney DG, Atkinson SD, Moore JE, Maurizi E, Serafini C, Pellegrini G et al. Development of allele-specific gene-silencing siRNAs for TGFBI Arg124Cys in lattice corneal dystrophy type I. Invest Ophthalmol Vis Sci 2014; 55: 977-985
10. Courtney DG, Atkinson SD, Allen EHA, Moore JE, Walsh CP, Pedrioli DML et al. siRNA silencing of the mutant keratin 12 allele in corneal limbal epithelial cells grown from patients with Meesmann?s epithelial corneal dystrophy. Invest Ophthalmol Vis Sci 2014; 55: 3352-3360
11. Allen EHA, Atkinson SD, Liao H, Moore JE, Leslie Pedrioli DM, Smith FJD et al. Allele-specific siRNA silencing for the common keratin 12 founder mutation in Meesmann epithelial corneal dystrophy. Invest Ophthalmol Vis Sci 2013; 54: 494-502
12. Schwank G, Koo B-K, Sasselli V, Dekkers JF, Heo I, Demircan T et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 2013; 13: 653-658
13. Yin H, Xue W, Chen S, Bogorad RL, Benedetti E, Grompe M et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 2014; 32: 551-553
14. Wu Y, Liang D, Wang Y, Bai M, Tang W, Bao S et al. Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell 2013; 13: 659-662
15. Cao T, Longley MA, Wang X, Roop DR. An inducible mouse model for epidermolysis bullosa simplex: implications for gene therapy. J Cell Biol 2001; 152: 651-656
16. Blair-Parks K, Weston BC, Dean DA. High-level gene transfer to the cornea using electroporation. J Gene Med 4: 92-100
17. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc 2013; 8: 2281-2308
18. Atkinson SD, McGilligan VE, Liao H, Szeverenyi I, Smith FJD, Moore CBT et al. Development of allele-specific therapeutic siRNA for keratin 5 mutations in epidermolysis bullosa simplex. J Invest Dermatol 2011; 131: 2079-2086
19. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012; 9: 671-675
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) Method. Methods 2001; 25: 402-408
21. Pfaffl MW, Tichopad A, Prgomet C, Neuvians TP. Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper - Excel-based tool using pair-wise correlations. Biotechnol Lett 2004; 26: 509-515
22. Moore JE, McMullen CBT, Mahon G, Adamis AP. The corneal epithelial stem cell. DNA Cell Biol 21: 443-451